CTCs Detection from Intraoperative Salvaged Blood in RCC-IVC Thrombus Patients by Negative Enrichment and iFISH Identification - A Preliminary Study

Xiaoqing Zhang
Peking University Third Hospital

Xiangyang Guo
Peking University Third Hospital

Yanan Zong
Peking University Third Hospital

Chuanya Xu
Peking University Third Hospital

Jilian Wang
Peking University Third Hospital

Bin Zhang
Peking University Third Hospital

Chang Liu
Peking University Third Hospital

Yueqing Gong
Peking University Third Hospital

Lixiang Xue
Peking University Third Hospital Department of Radiology

Lulin Ma
Peking University Third Hospital

Shudong Zhang
Peking University Third Hospital

Yi Li
Peking University Third Hospital

Hong Zeng (dr_zeng@sina.com)
Peking University Third Hospital

Research article

Keywords: renal cell carcinoma, inferior vena cava thrombus, intra-operative cell salvage, leukocyte depletion filter, aneuploidy.

DOI: https://doi.org/10.21203/rs.3.rs-71616/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Intra-operative cell salvage (IOCS) and leukocyte-depleted filter (LDF) are widely used and effective in saving blood. However, the safety issue concerning reinfusion of IOCS-LDF processed blood to renal cell carcinoma (RCC) patients with inferior vena cava (IVC) thrombus were inconclusive for fear of increased risk of cancer metastases. This study intends to analyze the circulating tumor cell (CTC) eliminating effect of IOCS-LDF in 5 RCC-IVC thrombus patients.

Methods: A novel strategy integrating negative enrichment by immunomagnetic beads and immunostaining-fluorescence in situ hybridization with probes identifying aneuploid of 8 and/or 7 were used to detect CTCs from salvages blood. Blood samples were collected from 4 stages in each patient.

Results: The CTCs number decreased (from 3, 4, 10, 7, 3, respectively, to all zero) after IOCS-LDF treatment. And the triploidy of chromosome 7 and/or chromosome 8 were most common karyotype for RCC patients with IVC thrombus. Tetraploid of chromosome 8 concurred in only one sample and no polyploid (number of chromosome>4) were found.

Conclusion: IOCS-LDF might be a viable option for reduction of allogeneic product transfusion based on current preliminary outcome. More convincing conclusions are to be drawn with enlarged sample size and long-term follow-up of patients prognosis.

1. Background

Renal cell carcinoma (RCC) ranks the sixth most frequently diagnosed cancer in men and the 10th in women worldwide. It is the 13th most common cause of cancer death worldwide according to data provided by the World Health Organization, as more than 140,000 RCC-related deaths yearly. The incidence rates of RCC is still rising, and this is partly because the increase in the imaging examination. Although most detected lesions are small tumors, locally advanced disease continues to be diagnosed in a notable proportion of patients, with up to 17% of patients harboring distant metastases at the time of diagnosis [1].

It is observed in 4 - 10% RCC patients who have a unique propensity for vascular invasion (into the renal vein and inferior vena cava) in the advanced stage [2]. Current guidelines recommend surgical excision of non-metastatic RCC with inferior vena cava (IVC) thrombosis in patients with acceptable performance status [3]. Patients with RCC - IVC tumor thrombus had a significant blood loss during operation despite improvements in surgical technique. The median estimated blood loss was 1900 (IQR 800-3300) ml. For patients with thrombus level ≤ 2 and ≥ 3 (Mayo-level), the blood loss were 1500 (IQR 600-2875) ml and 3000 (IQR 1400-5350) ml, respectively [4]. Massive transfusion of allogeneic blood may cause bacterial infection, allergic reactions, hemolytic reactions, transfusion-related risks of acute lung injury and viral infections. In addition, the banked blood has low oxygen carrying capacity and impaired red blood cell viability [5]. Immune reactions may occur during allogeneic blood transfusion, leading to acute cell rejection. Allogeneic transfusion is an independent risk factor for cancer-specific mortality and overall mortality in patients with malignancies [6]. It is concerned that allogeneic transfusion may result in immunosuppression and possible adverse effects on urological cancer recurrence [7, 8].

Intra-operative cell salvage (IOCS) is of great significance in saving blood and offers an efficacious, alternative technique for blood replacement. Leukocyte-depleted filter (LDF) is normally used after IOCS washing and before infusion to remove nucleated cells such as bacteria and tumor cells. At present, IOCS is widely used in many surgeries like cardiac surgery and spinal orthopedic surgery [9]. Guidance from the UK National Institute for Health and Clinical Excellence (NICE) recommends the routine use of IOCS in all patients undergoing radical pelvic urological surgery in 2008 [10]. Though several meta-analysis of long-term follow up of cancerous patients after IOCS-LDF use were reported with no apparent risk of decreased long-term survival from oncological perspective [5,11], concerns regarding the increased risk of cancer recurrence or development of metastases resulting from re-infusion of malignant cells renders the reluctance of adopting IOCS-LDF. At present, there were few studies on the safety assessment of recovered blood in patients with RCC-IVC thrombus. This study intends to analyze the tumor cell eliminating effect of IOCS-LDF in patients with RCC-IVC thrombus with a novel strategy integrating negative enrichment by immunomagnetic beads and immunostaining-fluorescence in situ hybridization (NE-iFISH) with probes identifying aneuploidy.

2. Method

2.1 Patients selection

We recruited patients with RCC-IVC thrombus underwent open/laparoscopy radical nephrectomy and IVC tumor thrombectomy from January to December, 2018 in Peking University Third Hospital. Thrombus level was defined according to Mayo classification [12]. Only RCC - IVC thrombus (Mayo-levels II–IV) were included in the study. Excluding criteria: patients with blood diseases, infectious diseases, and those who refused to participate in the study. The study was approved by the hospital ethics committee (No. M2017296), and patients and their families all signed informed consent. Patients’ demographic information were recorded (Table 1).

2.2 Anesthesia and surgical methods:

General anesthesia was performed. Patients’ vital signs were closely monitored and the depth of anesthesia was adjusted according to surgical stimulus, BIS and dynamic circulation variation. Allogeneic blood transfusion was used according to transfusion guidelines and therapies. The surgery of open/laparoscopy radical nephrectomy and IVC tumor thrombectomy were dictated by the extent and level of the tumor thrombus, and the surgical technique has been described in detail by Berczi [13]. Surgical time, intraoperative blood loss, the amount of autologous blood recovery, and the amount of allogeneic blood transfusion were recorded. Recovered blood was not re-infused as this was not allowed by the ethical committee for fear of tumor dissemination and subsequent risk of metastatic disease. Tumor recurrence rate was investigated at 20 months follow up.

2.3 IOCS-LDF
The suction tube and blood reservoir of the IOCS machine (Cell Saver Elite, Haemonetics Corporation, MA, U.S.) was rinsed and pre-filled with 50-100ml anticoagulant saline (heparin saline, 500 IU/ml). The negative pressure of the suction device is set at 120 - 150 mmHg. The anticoagulant drip rate was adjusted to about 1 drop/second, and the flow rate was adjusted according to the amount and speed of the bleeding. All intraoperative shed blood was recovered from the skin incision to tumor removal. Recovered blood was anti-coagulated and washed with sterilized saline (1500~2000 ml for 250 ml RBC). After washing, the recruited blood was filtered through PALL® leukocyte reduction filter (SB, Haemonetics Corporation, MA, U.S.). Blood products treated with IOCS - LDF are for research use only and are not returned to patients.

2.4 Sample preparation

Blood samples were collected intraoperatively at 4 different stages and sites (S1, peripheral venous blood from internal jugular vein before skin incision; S2, blood sampled in the vena cava around the tumor thrombus during surgery; S3, IOCS blood after washing and before LDF filtering; S4, blood sampled from post-LDF filtration). Each sample contains 4.0 ml blood (figure 1).

2.5 Negative Enrichment of CTC

The strategy of enrichment for circulating tumor cell (CTCs) is performed according to manufacturer's instructions. Briefly, 4.0 ml blood samples were lysed by RBC hypotonic hemolysis. Solution was centrifuged at 300 ×g for 5 min. Then, the residue cell pellet was resuspended in PBS and subsequently incubated with anti-CD45 monoclonal antibody-coated magnetic beads for 30 min, followed by the separation of magnetic beads using a magnetic stand (Promega, Madison, WI, USA). Supernatants were subsequently subjected to identification.

2.6 Immunocytochemistry staining of CTCs

The identification of enriched CTCs was performed by combing the chromosome enumeration using fluorescence in situ hybridization (FISH) with chromosome 7 (green) and 8 (orange) centromere probes (Abbott Molecular Diagnostics, Des Plaines, IL, USA) and anti-CD45 monoclonal antibody (red) (CD45-FISH). Probe chromosome 7 (CEP7, green), chromosome 8 (CEP8, orange) and specimen were hybridized at 37°C for 20 min in hybridizer (DAKO). Then they were washed in 50 % formamide at 43°C for 15 min, and subsequently immersed into 2×SSC and gradient alcohol again. Specimens were washed twice with 0.2 % BSA and incubated with the CD45 mixture/2 %BSA conjugated to Alexa Fluor 594 (Invitrogen) for 1 h. Afterward, samples were washed again with 0.2 % BSA, and covered with DAPI which contained Vectashield mounting medium [14]. CTCs were examined and identified as hyperdiploid CEP8+/DAPI+/CD45-, hyperdiploid CEP7+/DAPI+/CD45- and hyperdiploid CEP7+, 8+/DAPI+/CD45- by two independent pathologists, while cells with CD45+ were differentiated as WBC.

2.7 Statistical Analysis

All data were recorded and compared among 5 RCC-IVC thrombus patients. Medians and quartiles were used to describe the amount of intraoperative blood loss, transfusion and recovered blood.

3. Results

3.1 Demographic Information

In the current study, a total of 5 patients with RCC - IVC thrombus were included for surgical treatment. Of all these 5 patients, one (case No. 2) underwent radical nephrectomy of the right kidney due to renal cancer in local hospital 3 years ago. The patient complained shortness of breath recently and was admitted to our hospital. His lung CT revealed multiple nodules in both lungs, indicative of metastasis (4.1cm*3.8 cm). Abdominal CT revealed IVC thrombosis which was operated later and diagnosed from clear cell renal cell carcinoma origin by pathological examination. The size of the renal tumors of the other four patients were 7.1 cm * 5.2 cm * 4.6 cm, 12 cm *10 cm * 6 cm, 5 cm * 3 cm * 2.5 cm, 9 cm * 5 cm * 4 cm, respectively, and the WHO/ISUP grading system of the tumors were G2, G3, G2, G3, respectively [15] (Table 2). The pathological diagnosis of all 5 patients were clear cell renal cell carcinoma (ccRCC) (Figure 2). Post-operative follow-up showed the patient (case No. 2) with radical nephrectomy history died of emphysema 16 months after thrombectomy. Other 4 patients were closely followed up for at least 20 months and no cancer recurrence or metastasis were found till now.

3.2 Intraoperative blood loss and recovery

A total of 5 patients (ASA II -III) were enrolled, including 1 female and 4 male patients, with an averaged age of 58.6 years. 3 patients (2 with Mayo-levels II, and 1 with Mayo-level IV) underwent open radical nephrectomy and IVC tumor thrombectomy, 1 (Mayo-level III) with open thrombectomy, and 1 patient (Mayo-level II) received laparoscopic radical nephrectomy and IVC tumor thrombectomy. Surgical duration was 335 (IQR, 320 - 540) min. The total intraoperative blood loss was 10,500 ml, 2100 (IQR, 1500 - 2700) ml, with one patient (Mayo-level IV) lost 4000 ml. The amount of transfused allogeneic red blood cells was 8800 ml, 2000 (IQR, 1200 - 2000) ml, and the amount of transfused plasma was 2800 ml. One patient (Mayo-level II) who underwent laparoscopic radical nephrectomy and IVC tumor thrombectomy did not receive allogeneic blood transfusion due to small amount of blood loss. A total amount of 5150 ml of autologous blood, 1000ml (750, 1300) was recovered during surgery (Table 2). One patient (Mayo-level IV) experienced major bleeding and was managed with vasoactive drugs and massive blood product transfusion and fluid resuscitation. All patients’ vital signs were stable during hospitalization.

3.3 Detection of tumor cells

20 blood samples from 5 RCC-IVC thrombus patients were studied. After excluding CD45+ leukocytes by immunomagnetic beads, the aneuploidy (abnormal chromosome numbers) of chromosome 8 and/or 7 were detected with IFISH examination. The aneuploidy of chromosome 8 or 7 include: trisomy 8,
tumor cells were only found on the internal surface of the heart-lung machine arterial filters. No distant metastasis was found in situations like combined oncologic and cardiovascular surgery without increasing the risk of hematogenous tumor dissemination. Postoperative cytological analysis and also for further study of the clinical significance in treatment efficacy of tumor recurrence, metastasis detection and prognosis.

It is interesting to note that CTCs recovered from intraoperative blood in ccRCC-IVC thrombus patients have the propensity of developing trisomy of chromosome 7 or other aberrant chromosome number ≥4 were detected. (Table 4).

4. Discussion

4.1 Aneuploidy of detected viable tumor cells

Intraoperative tumor metastasis occurred when large amounts of cancer cells were shed from primary tumor focus during surgical manipulation into the blood stream, becoming circulating tumor cells (CTC) and may target distant organs and develop metastatic tumors [16]. Reinfusion of viable tumor cells from intraoperative recovered blood poses potential risks of tumor dissemination and metastasis. However, due to scarce number of residual tumor cells from vast majority of leukocytes, capturing viable tumor cells from shed blood after IOCS-LDF treatment is difficult. Mi Sook Gwak reported using LDF to reduce the risk of reintroduction of hepatocellular carcinoma cells with PCR found that at high HCC cell load the filter cannot completely remove all the tumor cells [17]. Though PCR can detect CTCs gene copy numbers, accurate enumeration of CTCs by this strategy is not feasible [18]. Moreover, this method could not completely eliminate the interference from fragmented DNA in sampled blood. Other studies analyzed the remaining tumor cells using flow cytometry or immunohistopathological study in cell blocks or cultured cells found that no viable tumor cells could be detected or if there were any tumor cells found, the load was far less than the CTC numbers in the patients’ circulation [19,20]. However, restricted to the sensitivity and specificity of the above mentioned technologies, the isolation and capturing of viable tumor cells which were only several to several tens of number present in 1 ml of blood that contains billions of other cells were extremely difficult.

Currently, the majority of the methodology of detecting CTCs are restricted to the tumor cell density, size, and charge as well as biomarkers using antigen expression profiles and specific tumor antigen–antibody interactions to distinguish and isolate CTCs from other cells. However, a large quantity of primary CTCs are of smaller cell size (≤ WBCs) which makes it difficult to separate from WBC, and the rare CTCs are inevitably lost during filtration based cell size selection strategy [21]. Moreover, it is reported that positive EpCAM expression rate ranges 37% - 42.3% of the various cancers with FDA-approved CellSearch system. The invasive tumor cells tend to loose their epithelial antigens by the epithelial to mesenchymal transition process, which results in loss of EpCAM on CTCs and made the capturing of CTCs more difficult [22]. On the other hand, capturing non-tumor derived epithelial cells originated from inflammation, trauma, surgery and benign epithelial hyperplasia may cause false positive results [23]. For renal cell carcinoma, the expression of EpCAM was absent and there is no widely acknowledged specific cell surface marker for RCC detection [24,25]. Therefore, a promising alternative approach of EpCAM-independent enrichment strategy has been introduced [26].

In this preliminary study, detecting aberrant chromosome is attempted as a way of capturing tumor cells in RCC patients. Aneuploidy is the abnormal alternation (either gain or loss) of chromosomes in a cell. It is estimated that 90% of solid tumors exhibit aneuploidy [21]. By integrating cellular and molecular approach of negative enrichment and immunostaining-fluorescence in situ hybridization (NE-iFISH), which is independent of cell size variation and free of anti-EpCAM perturbation, iFISH could simultaneously co-detecting biomarker expression qualitatively and quantitatively, as well as discovering chromosome aneuploidy [14, 27].

It is reported that unique molecular alterations such as loss of 3p and trisomy of chromosomes 7 is well characterized for clear cell and papillary RCC [28-31]. After negative enrichment, tumor cells are identified by iFISH. Aneuploidy of chromosome 8 and/or 7 were analyzed and tumor cells were differentiated (figure 3). In this way, we could separate CTCs from recovered blood in RCC with IVC thrombus patients. To our knowledge, this is the first time that aneuploidy of aberrant chromosomes detection method was adopted with NE-iFISH to capture CTCs in the recovered blood of ccRCC patients with encouraging result.

It is interesting to note that CTCs recovered from intraoperative blood in ccRCC-IVC thrombus patients have the propensity of developing trisomy of chromosome 7 or 8. This chromosome karyotype was not reported before and deserve further exploration. It may be useful for future chromosome karyotype analysis and also for further study of the clinical significance in treatment efficacy of tumor recurrence, metastasis detection and prognosis.

4.2 IOCS-LDF and RCC metastasis

Radical nephrectomy and IVC tumor thrombectomy is widely acknowledged as the curative method for patients with RCC-IVC thrombus [32]. When the tumor thrombus extends to the right atrium, intraoperative establishment of extracorporeal circulation is required. Patients with Mayo-level III-IV often experienced life-threatening intraoperative major bleeding. As blood resource is limited, scheduled surgeries are always delayed. A recent meta-analysis has shown that the infusion of allogeneic blood during radical prostatectomy, radical nephrectomy and cystectomy lead to worsened prognosis for patients [33], and this may be related to transfusion-related immunomodulation [34]. The application of IOCS-LDF is an effective alternative for massive blood transfusion. A study concerning the IVC tumor thrombus extending to right atrium has shown that the use of cardiopulmonary bypass and cell-saver technique in borderline situations like combined oncologic and cardiovascular surgery without increasing the risk of hematogenous tumor dissemination. Postoperative cytological investigation showed that the tumor cells were only found on the internal surface of the heart-lung machine arterial filters. No distant metastasis was found in all surviving patients [35].
There were limited clinical study concerning the safety of returning shed blood to RCC-IVC thrombus patients. Moskowitz reported a Jehovah's Witness patient with RCC-IVC thrombus extending into the right atrium underwent surgery received the return of 3 L of salvaged erythrocytes during surgery without immediate complication, but the patient's long-term outcome was not reported [16]. A study including 10 patients underwent radical nephrectomy with IVC and atrial thrombi surgery was followed-up for 46 months. Unfortunately, the only use of IOCS in conjunction with cardiopulmonary bypass renders the conclusions difficult to ascertain, and comparisons between the usage of IOCS are confounded by disease severity and level of caval thrombus [36].

Timothy D reported 67 renal cancer patients undergone partial nephrectomy using IOCS-LDF without increasing postoperative complications or tumor recurrence, and 2 years of follow-up showed no metastasis [37]. Another retrospective cohort study was performed to assess the impact of intra-operative cell salvage on outcomes in open nephrectomy with 16 patients using IOCS and 24 without, concluding that IOCS appears to be a safe way with low rates of tumor recurrence and complications [38]. A meta-analysis in 2019 systematically evaluated the safety and effectiveness of IOCS in urological procedures by comparing the rate of allogeneic blood transfusion and tumor recurrence, complications, and medical costs. For the 14 observational studies (4536 patients) that were finally included, compared with other blood protection methods, IOCS was considered to reduce the rate of allogeneic blood transfusions and reduce medical costs, without affecting the incidence of complications. The author concluded from 10 studies that tumor recurrence was found to be significantly less common or similar in IOCS group. Eight of the studies were performed on prostate surgery, and only one was followed up for more than 5 years [39]. For nephrectomy and cystectomy, tumor recurrence after IOCS needs to be further studied.

4.3 Leukocyte filter and tumor cell filtration

Leukocyte depletion filter (LDF) is a filtering device based on a membrane-like filter material to remove leukocytes from blood. Its mechanism for removing tumor cells is physical interception and charge adsorption based on cell size. Study from hepatocellular carcinoma cells has shown that once the cell number exceeds 1 × 10^3, LDF cannot effectively filter tumor cells [40]. Hanse compared 9 different LDF filters and found that the reduction rates of tumor cell lines is within the range of 4-5 log, but only 3 log of prepared cells from solid tumor could be filtered. It is estimated that up to 10^7 tumor cells were shed during oncologic surgery, therefore it is unsafe to return autologous blood after LDF filtration [41]. In many types of tumor surgery, the actual number of shed tumor cells ranges approximately 0.2-4000/ml [42]. Existing evidence suggested that only for malignancies of advanced stage or tumor rupture during surgery can there be possibilities of ineffective clearance of LDF. Kai Mei and colleague reported by applying mannitol-adenine-phosphate (MAP) solution, the tumor cell clearance rate was increased from 2-3 log to 4-5 log with modified-LDF (M-LDF). For blood mixed with HepG2 cell (10^6-10^7), 67% inoculated nude mice developed tumors with unfiltered blood, while no solid tumor appeared in inoculated nude mice after filtering with M-LDF [43]. Therefore, it is considered that M-LDF with MAP had higher filter efficiency, but further clinical evidence is warranted. In the current study, we demonstrated with aneuploidy method, all the tumor cells in 5 patients were completely removed after LDF treatment, and intraoperative IOCS-LDF usage could clear all tumor cells in RCC-IVC thrombus patients with high efficiency.

4.4 IOCS-LDF for RCC-IVC thrombus tumor cell removal

In this study, 5 RCC-IVC thrombus patients were enrolled and 20 blood samples taken at different sites and stages during surgery were studied. Samples of S1 is indicative of the circulating tumor cells; S2 indicated peri-thrombus tumor cells shedding into inferior vena cava during operation; S3 represents the tumor cell cleaning efficacy with IOCS; and S4 is the actual final filtering result after LDF. Tumor cell numbers from all S4 samples were zero after IOCS-LDF treatment. To our surprise, the number of tumor cells in internal jugular vein from S1 is most abundant (3, 4, 10, 7 and 3, respectively), while the number from S2 decreased dramatically (0, 0, 2, 5 and 1). This might be explained by the solid texture of the IVC thrombus and its smooth surface which could extend itself way up to the atrium without being flushed away by blood flow in the inferior vena cava. This also indicate that intraoperative exploration of the tumor thrombus does not necessarily result in significant shedding of tumor cells which might lead to tumor dissemination. Our study also demonstrated that IOCS alone is not enough for tumor cell depletion as CTCs were still detected in 2/5 cases from S3. The IOCS-LDF is efficient in depleting tumor cells from recovered blood as the number of CTCs reduced to 0 in all S4 samples. Due to limited sample size, further research with enlarge sample size is needed to verify the clearance ability of IOCS-LDF on RCC-IVC thrombus cases. Considering cell size differences, the application of IOCS-LDF to other tumor types may not achieve the equivalent effect.

Moreover, we also found that there is no close correlation between the amount of blood loss and the number of CTCs from the current study, which was also stated by Emil Hansen in their research [42]. The number of CTCs were more prominent in patients with more advanced tumor stage and higher WHO-ISUP grading as well as Mayo-level grading. In case 3 and 4, the Mayo-level grading were II and IV, and the WHO-ISUP grading were G3 and G2, respectively. In case 3, the number of CTCs were 10 (S1) and 3 (S2), and the size of the dissected tumor is 12 cm*10 cm*6 cm; while for case 4, the number of CTCs were 7 (S1) and 5 (S2), with the size of the dissected tumor 5 cm*3 cm*2.5 cm. However, it is arbitrary to reach any definitive conclusion based on the limited sample size. Further research is warranted in verifying this finding.

5. Conclusion

As there were no definitive guidelines or experts consensus to support the intraoperative use of IOCS-LDF in renal cell carcinoma patients, and the safety of laboratory and clinical evidence of reinfusion of autologous blood is lacking, therefore, our hospital forbid this procedure and only allow the experimental study of tumor cell deleting effect of the IOCS-LDF. In this preliminary study, CTCs of all samples decreased to 0 after IOCS-LDF in all five RCC-IVC thrombus patients detected by NE-I-FISH, with encouraging results. More convincing conclusions are to be drawn with enlarged sample size and discovery of more specific and accurate bio-markers for tumor cells originated from RCC-IVC thrombus.

List Of Abbreviations
IOCS: Intra-operative cell salvage
LDF: leukocyte-depleted filter
RCC: renal cell carcinoma
IVC: inferior vena cava
CTC: circulating tumor cell
NE-iFISH: negative enrichment by immunomagnetic beads and immunostaining fluorescence in situ hybridization
FISH: fluorescence in situ hybridization
M-LDF: modified-LDF
MAP: mannitol-adenine-phosphate

Declarations

Ethics approval and consent to participate

The experimental protocol was established, according to the ethical guidelines of the Helsinki Declaration and was approved by the Human Ethics Committee of Peking University Third Hospital. Written informed consent was obtained from individual participants.

Availability of data and material

All data generated or analysed during this study are included in this published article.

Competing interests

The author(s) declare no competing interests.

Funding

This work was supported by the Clinical Key Project of Peking University Third Hospital, Grants No. BYSY2017001.

Authors' contributions

Guarantor of integrity of entire study: H Zeng, Y Li, XY Guo
Study concepts Study design: H Zeng, XY Guo
Literature research: XQ Zhang, XY Guo, JL Wang
Clinical studies: XQ Zhang, YN Zong, CY Xu, B Zhang, C Liu
experimental studies: XQ Zhang, YQ Gong, LX Xue
Data acquisition: XQ Zhang, LL Ma, SD Zhang
Data analysis/interpretation: XQ Zhang, Y Li, H Zeng
Statistical analysis: XQ Zhang, XY Guo, JL Wang
Manuscript preparation: XQ Zhang, XY Guo, JL Wang, YQ Gong, LX Xue, H Zeng
Manuscript editing and revision: Y Li, H Zeng, XY Guo, JL Wang
Manuscript final version approval: H Zeng, XY Guo
all authors have read and approved the manuscript.

Acknowledgments

None.

References

9. 10.1002


Tables

Table 1

<table>
<thead>
<tr>
<th>Case</th>
<th>Age (y)</th>
<th>Gender</th>
<th>Mayo-level grading</th>
<th>Surgical duration (min)</th>
<th>Tumor size (cm)</th>
<th>WHO/ISUP grading</th>
<th>Pathological diagnosis</th>
<th>20-mon follow-up</th>
<th>Tumor recurrence or metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>63</td>
<td>M</td>
<td>□</td>
<td>553</td>
<td>7.1<em>5.2</em>4.6</td>
<td>G2</td>
<td>ccRCC</td>
<td>alive</td>
<td>none</td>
</tr>
<tr>
<td>2*</td>
<td>49</td>
<td>M</td>
<td>□</td>
<td>350</td>
<td>—</td>
<td>—</td>
<td>ccRCC</td>
<td>dead</td>
<td>Preoperative lung metastasis</td>
</tr>
<tr>
<td>3</td>
<td>48</td>
<td>M</td>
<td>□</td>
<td>161</td>
<td>12<em>10</em>6</td>
<td>G3</td>
<td>ccRCC</td>
<td>alive</td>
<td>none</td>
</tr>
<tr>
<td>4</td>
<td>75</td>
<td>M</td>
<td>□</td>
<td>320</td>
<td>5<em>3</em>2.5</td>
<td>G2</td>
<td>ccRCC</td>
<td>alive</td>
<td>none</td>
</tr>
<tr>
<td>5</td>
<td>60</td>
<td>F</td>
<td>□</td>
<td>540</td>
<td>9<em>5</em>4</td>
<td>G3</td>
<td>ccRCC</td>
<td>alive</td>
<td>none</td>
</tr>
</tbody>
</table>

* The patient underwent radical right nephrectomy for renal cancer 3 years ago. Now he was diagnosed as inferior vena cava thrombus with lung metastasis. The patient died of emphysema 16 months after surgery.

ISUP, International Society of Urological Pathology. G2, Tumour cell nucleoli conspicuous and eosinophilic at 400 × magnification and visible but not prominent at 100 × magnification; G3, Tumour cell nucleoli conspicuous and eosinophilic at 100 × magnification.

ccRCC, clear cell Renal Cell Carcinoma.
Table 2
Intraoperative blood loss and the transfusion.

<table>
<thead>
<tr>
<th>Case</th>
<th>Total blood loss (ml)</th>
<th>Infused RBC (ml)</th>
<th>Infused plasma (ml)</th>
<th>Recovered blood (ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2700</td>
<td>2000</td>
<td>0</td>
<td>1300</td>
</tr>
<tr>
<td>2</td>
<td>1500</td>
<td>1200</td>
<td>400</td>
<td>750</td>
</tr>
<tr>
<td>3</td>
<td>200</td>
<td>0</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>4</td>
<td>2100</td>
<td>2000</td>
<td>800</td>
<td>1000</td>
</tr>
<tr>
<td>5</td>
<td>4000</td>
<td>3600</td>
<td>1600</td>
<td>2000</td>
</tr>
<tr>
<td>Median IQR (ml)</td>
<td>2100 1500–2700</td>
<td>2000 1200–2000</td>
<td>400 0–800</td>
<td>1000 750–1300</td>
</tr>
</tbody>
</table>

IQR, inter quartile range.
Table 3
CTC counts of aneuploidy of chromosome 8 and/or 7 from blood samples.

<table>
<thead>
<tr>
<th>Case</th>
<th>Sample</th>
<th>CTC counts</th>
<th>Triploid of chromosome 8</th>
<th>Tetraploid of chromosome 8</th>
<th>Polydiploid (4) of chromosome 8</th>
<th>Triploid of chromosome 7</th>
<th>Tetraploid of chromosome 7</th>
<th>Polydiploid (4) of chromosome 7</th>
<th>Polydiploidy chromosome of both 7 and 8</th>
<th>CTM</th>
<th>Sum</th>
<th>Total num</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>S1</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>S2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S3</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>S4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>S1</td>
<td>1</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1*</td>
</tr>
<tr>
<td></td>
<td>S2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S3</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>S4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>S1</td>
<td>6</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>S2</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>S3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>4</td>
<td>S1</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>S2</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1*</td>
</tr>
<tr>
<td></td>
<td>S3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>S1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1*</td>
</tr>
<tr>
<td></td>
<td>S2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>S3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
</tbody>
</table>

Number 0 were not shown in the table.

*, triploid of both chromosome 8 and 7

Tumor cells were recognized and counted using immunostaining and fluorescence in situ hybridization technology. Only cells with CD45-/DAPI+/CEP8+ (2), CD45-/DAPI+/CEP8+ (2), and CD45-/DAPI+/CEP8+ and CEP7+ (hyperdiploidy) were identified as CTCs.

CTM, Circulating Tumor Microemboli.

S1, peripheral venous blood sample from internal jugular vein before skin incision, indicative of the circulating tumor cells;

S2, blood sampled in he vena cava around thrombus during surgery, indicating direct cells shedding in surgical manipulation;

S3, blood after IOCS washing and before LDF filtering, which represents the tumor cell cleaning efficacy with only IOCS;

S4, blood sampled after LDF filtration, meaning the actual final filtering result after IOCS-LDF.
<table>
<thead>
<tr>
<th>sample</th>
<th>Case numbers</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>chromosome 8 triploidy</td>
<td>chromosome 8 tetraploidy</td>
<td>chromosome 7 triploidy</td>
<td>Chromosome 7 and 8 hyperdiploidy</td>
<td></td>
</tr>
<tr>
<td>S1</td>
<td>5</td>
<td>1</td>
<td>4</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>S2</td>
<td>2</td>
<td></td>
<td>3</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>S3</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>8</td>
<td>1</td>
<td>8</td>
<td>3</td>
<td></td>
</tr>
</tbody>
</table>

Triploidy of chromosome 8 were detected in 8 cases: 5/5 cases in S1, 2/5 cases in S2 and 1/5 cases in S3;

Triploidy of chromosome 7 were detected in 8 cases: 4/5 cases in S1, 3/5 cases in S2, and 1/5cases in S3;

The hyperdiploidy of both chromosome 7 and 8 were detected in 3 cases: 2 cases of S1 and 1 case of S2;

Only 1 case with tetraploidy of chromosome 8;

No tetraploidy of chromosome 7, or other aberrant chromosome number $\geq$ 4 were detected.